Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intra-Cellular Therapies

131.87
+0.0000
Volume:- -
Turnover:- -
Market Cap:14.02B
PE:-182.12
High:131.87
Open:131.87
Low:131.87
Close:131.87
Loading ...

Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects

TIPRANKS
·
22 Feb

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
21 Feb

Intra-Cellular Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
21 Feb

Intra-Cellular: Q4 Earnings Snapshot

Associated Press Finance
·
21 Feb

Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
21 Feb

Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Net Loss $0.16 a Share, vs. FactSet Est of $0.07 Loss

MT Newswires Live
·
21 Feb

Intra-Cellular Therapies Inc Q4 Shr Loss $0.16

THOMSON REUTERS
·
21 Feb

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

GlobeNewswire
·
21 Feb

J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?

Zacks
·
17 Feb

The M&A Boom Of 2025 Is Just Getting Started - And Here Are 5 Potential Targets

Dow Jones
·
09 Feb

Steady M&A Deals to Begin 2025, Disappointing IPOs So Far

GuruFocus.com
·
05 Feb

UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating

MT Newswires Live
·
05 Feb

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119

MT Newswires Live
·
31 Jan

Intra-Cellular Therapies Inc : Canaccord Genuity Cuts to Hold From Buy; Raises Target Price to $132 From $119

THOMSON REUTERS
·
31 Jan

Intra-Cellular downgraded to Hold from Buy at Canaccord

TIPRANKS
·
31 Jan

J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)

TIPRANKS
·
29 Jan

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now

Insider Monkey
·
24 Jan

BUZZ-Street View: New drug launches, ITCI deal to boost J&J's growth

Reuters
·
23 Jan

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com
·
23 Jan

Intra-Cellular Therapies Cut to Sector Perform From Outperform by RBC Capital

Dow Jones
·
23 Jan